Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967173 · ClinicalTrials.gov registry record · Phase 3
Best African American Response to Asthma Drugs
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 574
- Enrollment target
NCT01967173: Completed Phase 3 study, sponsored by Milton S. Hershey Medical Center.
NCT01967173 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 574 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01967173, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 574 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.
Primary Outcome
This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of exacerbations. If one treatment results in fewer exacerbations than another, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by exacerbations, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs mo
Interventions
- DRUG Flovent Diskus® 100 mcg
- DRUG Flovent Diskus® 250 mcg
- DRUG Flovent Diskus® 500 mcg
- DRUG Advair Diskus® 100/50 mcg
- DRUG Advair Diskus® 250/50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 574 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-07-01 |
| Phase | Phase 3 |
What the finished NCT01967173 record still lists
NCT01967173 is an interventional study that assigns participants to a tested intervention. The registered 574 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 5 interventions - of which Flovent Diskus® 100 mcg is the first listed.
NCT01967173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01967173 about?
NCT01967173 is a clinical study titled "Best African American Response to Asthma Drugs". The purpose of this study is to find the best asthma treatment to add for Blacks who have asthma that is not well controlled on a low dose of inhaled steroid. This study will also try to find out if Black adults and children differ in how they respond to the medications used in this study.
What is the current status of trial NCT01967173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 574 participants. The study started on 2014-02. Estimated completion is 2017-07-01.
What interventions are being tested in trial NCT01967173?
The interventions under investigation include: Flovent Diskus® 100 mcg (DRUG), Flovent Diskus® 250 mcg (DRUG), Flovent Diskus® 500 mcg (DRUG), Advair Diskus® 100/50 mcg (DRUG), Advair Diskus® 250/50 mcg (DRUG).
Who is sponsoring clinical trial NCT01967173?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01967173's enrollment target sits among peer trials
574 663rd of 2000 higher than 1,338 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07349537 · 574 participants · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT05919264 · 575 participants · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia